Drugs & Targets FDA grants Breakthrough Therapy Designation for Astellas’ and Seattle Genetics’ agent Padcev in bladder cancer indication February 21, 2020Vol.46 No.08
Drugs & Targets FDA accepts Valoctocogene Roxaparvovec for Priority Review February 21, 2020Vol.46 No.08
Drugs & Targets FDA grants Priority Review for BMS agent lisocabtagene maraleucel February 14, 2020Vol.46 No.07
Drugs & Targets FDA grants Priority Review for Seattle Genetics agent tucatinib February 14, 2020Vol.46 No.07
Drugs & Targets FDA grants Nanobiotix Fast Track designation for investigation of NBTXR3 in head and neck February 14, 2020Vol.46 No.07
Drugs & Targets Myriad submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer February 14, 2020Vol.46 No.07
Drugs & Targets EMA accepts tucatinib application in HER2-positive breast cancer February 07, 2020Vol.46 No.06
Drugs & Targets EMA accepts application for belantamab mafodotin for multiple myeloma February 07, 2020Vol.46 No.06
Drugs & Targets European advisory group backs Pfizer’s Rituxan biosimilar February 07, 2020Vol.46 No.06
